Trial reportAesthetic plastic surgery2026
Integrated Topical Skincare Enhances Picosecond Laser Treatment Outcomes for Photoaging: A Prospective Split-Face Trial.
Trial report in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe 755-nm picosecond alexandrite laser with a diffractive lens array effectively treats photoaging in Asian patients but may cause transient adverse effects due to temporary disruption of the skin barrier.
objectiveThis study evaluated the efficacy and safety of a topical integrated skincare regimen containing CE Ferulic serum, Discoloration Defense (3% tranexamic acid), and Triple Lipid Restore 2:4:2 (CE/DD/242) following treatment with a 755-nm picosecond alexandrite laser with a diffractive lens array (DLA) in an Asian population.
methodsThis single-center, randomized, evaluator-blinded, split-face controlled study enrolled 35 patients aged 25-63 years with facial photoaging. Each patient underwent three laser treatment sessions at four-week intervals. Patients applied Phyto Corrective serum and sunscreen to one cheek (control side) and adjunctive CE/DD/242 to the other cheek (treatment side). Clinical efficacy was evaluated using the VISIA® Complexion Analysis System, the FocuSkin® Skin Analyzer, and a participant satisfaction questionnaire. Self-reported redness or swelling was recorded by telephone follow-up.
resultsLaser treatment significantly improved pores (p=0.0011), brown spots (p=0.0003), and skin moisture (p=0.0001). Adjunctive integrated skincare further enhanced wrinkle reduction (adjusted difference - 2.33, p=0.018) and texture improvement (adjusted difference - 0.63, p=0.027). Females over 46 years demonstrated greater wrinkle reduction (p=0.0437), while males showed greater elasticity improvement (p=0.0003). Temporary erythema occurred in 13 of 35 patients, while 18 reported no adverse effects. Patient satisfaction scores were higher on the CE/DD/242 treatment side.
conclusionsThe 755-nm picosecond alexandrite laser with a diffractive lens array improves photoaging and overall skin quality. Adjunctive integrated skincare (CE/DD/242) provides synergistic clinical benefits with minimal adverse effects, resulting in greater improvements in wrinkles and skin texture. LEVEL OF EVIDENCE I: Evidence obtained from at least one properly designed randomized controlled trial. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.